ArticleInternational journal of medical sciences2026
The relationship between 5α-reductase inhibitors and the presence of following open angle glaucoma: a TriNetX cohort study.
Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study was conducted to test a possible association between 5α-reductase inhibitor (5ARI) use and subsequent open-angle glaucoma (OAG). Method: A retrospective cohort study was conducted, and individuals with benign prostate hyperplasia (BPH) and androgenetic alopecia were included and classified according to whether they received 5ARI treatment. A total of 181,208 individuals were included in each of the 5ARI and non-5ARI groups. The primary outcome was the development of OAG according to diagnostic and procedure codes. Cox proportional hazard regression was performed for the statistical analysis. Results: OAG occurred in 3477 patients (5.14%) in the 5ARI group and 3044 patients (4.59%) in the non-5ARI group. After adjustment for multiple covariates, exposure to 5ARIs was associated with a significantly greater risk of OAG compared with the non-5ARI treatment (P < 0.001). The cumulative incidence of OAG was significantly higher among patients receiving 5ARI therapy than among those in the non-5ARI group (P < 0.001), and the cumulative incidence of HTG was significantly higher in the 5ARI population than the non-5ARI population (P = 0.002). In the sensitivity analysis, the 5ARI cohort exhibited significantly increased rates of OAG and HTG compared with the non-5ARI cohort, except for Asian individuals (P > 0.05). Conclusions: The use of 5ARIs may be related to the development of OAG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.